Developer docs
API playgroundTry for free, no card

Search company profiles

Marksans Pharma

Full company profile

uuid003314i

Namestring
Marksans Pharma
Legal namestring
Marksans Pharma Limited
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Marksans Pharma Limited is a publicly listed Indian pharmaceutical company (NSE: MARKSANS, BSE: 524404) that develops, manufactures, and markets finished dosage generic pharmaceutical formulations for global regulated markets. Founded in 2001 as a wholly-owned subsidiary of Glenmark Pharmaceuticals and spun off as an independent entity in 2003, the company operates four manufacturing facilities — two in Goa, India (Verna and North Goa), one in Farmingdale, USA (Time-Cap Labs), and one in Southport, UK — producing tablets, hard and soft gelatin capsules, oral liquids, and ointments. Combined annual capacity is 8 billion units, on track to double to 16 billion units following the Tevapharm India acquisition. The portfolio comprises 300+ products and 1,500+ SKUs across OTC consumer self-care (pain, cough/cold, allergy, digestive, vitamins, skin) and prescription therapeutic segments (cardiovascular, CNS, oncology, anti-diabetics, antibiotics), backed by 50+ FDA-approved products, 350+ filed dossiers, and 300+ ANDA/MA approvals.

The company runs a vertically integrated, B2B contract-manufacturing and distribution model. Revenue is generated through negotiated supply agreements with major retail chains, pharmacy wholesalers, and hospital systems in the US, UK, Europe, Australia, Canada, MENA, and emerging markets — 95% of revenue comes from regulated jurisdictions. Distribution is executed through wholly-owned subsidiaries: Time-Cap Labs (US), Bell's Healthcare and Relonchem (UK), Nova Pharmaceuticals (Australasia), Access Healthcare (MENA), and QliniQ B.V. (Netherlands, acquired June 2026). R&D is conducted across four centers with 50+ scientists accredited by US-FDA, UK MHRA, and Australian TGA. With FY26 consolidated revenue of approximately ₹29,509 million (~$355M USD) and net profit of ₹4,200.64 million, the company is positioned as a mid-tier Indian generic exporter with an accelerating M&A-led geographic expansion strategy across the US, EU, Canada, and Australasia.

Short descriptiontext

Marksans Pharma is an Indian publicly listed generic pharmaceutical manufacturer producing tablets, capsules, oral liquids, and ointments across four facilities in India, the US, and UK, distributing 300+ products through wholly-owned subsidiaries to retail chains, wholesalers, and hospitals in 50+ countries with 95% of revenue from regulated markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical formulations, OTC medications, prescription drugs, CRAMS services
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Formulations
TypeOne Time License
Description

Research, manufacturing, and marketing of finished dosage pharmaceutical formulations. Revenue generated from sale of generic drugs across OTC and prescription categories. The company operates in regulated markets (US, Europe, Australia) contributing 95% of revenue.

marksanspharma.com
2OTC Products
TypeOne Time License
Description

Over-the-counter consumer self-care products including pain management, cough and cold, digestive health, vitamins, supplements, and anti-allergic medications. Sold through retail chains and pharmacies.

marksanspharma.com
3Prescription (Rx) Drugs
TypeOne Time License
Description

Prescription medications for cardiovascular diseases, central nervous system disorders, diabetes, oncology, and antibiotics. Distributed through wholesalers, retailers, and hospitals.

marksanspharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B pharmaceutical sales model
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing is negotiated through contracts with pharmacy chains, wholesalers, retailers, and hospital groups. No public pricing list available.

marksanspharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Bells Healthcare
Description

Over-the-counter and prescription pharmaceuticals brand specializing in own-label products including analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care

marksanspharma.com
+4 more records
Core offering1 text field

Marksans Pharma is a publicly listed Indian pharmaceutical company that researches, manufactures, and markets finished dosage generic pharmaceutical formulations, including tablets, capsules, oral liquids, and ointments, across OTC and prescription segments. The company operates four manufacturing facilities in India, the UK, and the USA, producing over 300 products and 1,500+ SKUs distributed to retailers, wholesalers, and pharmacy chains in regulated markets globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FY26 net profit grew 9.8% to ₹4,200.64 million
+3 more records
Product overview1 text field

Marksans Pharma operates a diversified pharmaceutical formulation business with four manufacturing facilities located in India (Verna Goa and North Goa), United States (Farmingdale), and United Kingdom (Southport). The company offers a comprehensive portfolio of 300+ products and 1500+ SKUs across two main categories: OTC Consumer Self-Care Products (Pain Management, Cough & Cold, Allergy, Digestive Health, Vitamins/Minerals/Supplements, Skin Care) and Prescription Rx Therapeutic Segments (Cardiovascular, CNS, Oncology, Anti-Diabetics, Anti-Biotics). The portfolio is supported by subsidiary brands including Bells Healthcare (UK), Nova Pharmaceuticals (Australia), Relonchem (UK), Time-Cap Labs (USA), Access Healthcare (UAE/MENA), and QliniQ BV (Netherlands). Manufacturing capabilities include tablets, hard/soft gelatin capsules, oral liquids, and ointments with accreditations from US FDA, UK MHRA, Australian TGA, EU Health Authority, Health Canada, and Japanese Health Authority.

Product and service8 records
1OTC Consumer Self-Care Products
CategoryOTC Pharmaceuticals
Description

Over-the-counter consumer healthcare products including pain management (arthritis), upper respiratory (cough & cold, allergy), digestive health, vitamins/minerals/supplements, and skin care products distributed through retail and pharmacy chains.

2Prescription (Rx) Therapeutic Segments
CategoryPrescription Pharmaceuticals
Description

Prescription pharmaceutical products covering cardiovascular system, central nervous system, oncology, anti-diabetics, and anti-biotics therapeutic segments, distributed to wholesalers, retailers, and hospitals.

3Bells Healthcare (Bell, Sons & Co. Druggists) Ltd
CategoryOTC & Prescription Pharmaceuticals (UK)
Description

UK-based manufacturer of over-the-counter and prescription pharmaceuticals with over 100 MHRA-registered licenses, specializing in own-label products across analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care. Largest manufacturer of private-label and branded cough liquids in the UK.

4Nova Pharmaceuticals Australasia
CategoryOTC & Generic Pharmaceuticals (Australia)
Description

Australian pharmaceutical company engaged in R&D and marketing of generic OTC products with focus on analgesics, antihistamines, anti-fungal, anti-allergy, dermatology, essential oils, and gastrointestinal segments. All products comply with TGA Australia regulations.

5Relonchem Limited
CategoryPrescription Generic Pharmaceuticals (UK)
Description

UK-based company engaged in licensing, marketing, and distribution of prescription generic pharmaceutical products to wholesalers, retailers, and hospitals. Portfolio includes own-label products in anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, allergy relief, anti-viral, and pain relief categories.

6Time-Cap Labs Inc.
CategoryGeneric Pharmaceuticals (USA)
Description

US-based manufacturer of solid-dose generic pharmaceutical products operating in OTC and prescription pharmaceutical markets. Products include Gastrointestinal, Laxatives, Pain Management, Analgesics, Cold and Cough, and Anti-Allergy categories sold through major pharmacy chains, distributors, and wholesalers.

7Access Healthcare for Medical Products L.L.C.
CategoryPharmaceutical Distribution & Marketing (MENA)
Description

Dubai-based pharmaceutical marketing and promotion company providing strategic partners with opportunities to grow business in the MENA region, with in-depth knowledge of local pharmaceutical market and business culture.

8QliniQ BV
CategoryPharmaceuticals (EU/Specialty)
Description

Netherlands-based company representing world leading manufacturers of medical devices and medicines. Operates niche products across women's health, dermatology, respiratory care, and specialty segments, manufactured within EU with Netherlands, Germany, and Spain as main manufacturing countries.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian-headquartered generic pharmaceutical manufacturer with a comparable global footprint across the US, Europe, and emerging markets, similar dosage-form portfolio (oral solids, injectables, complex generics), and similar revenue scale. Both compete head-to-head in US generic ANDAs and UK/EU markets.

TypeDirect peer
Description

Indian pharmaceutical company with comparable India-manufacturing-plus-US-distribution model, similar therapeutic-area breadth across OTC and prescription generics, and overlapping US ANDA filings. Comparable revenue scale and growth profile.

3Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharmaceutical company and the dominant Indian generic player globally. Operates across the same dosage forms and therapeutic areas as Marksans but at substantially greater scale, with broader specialty and branded-generic exposure.

TypeDirect peer
Description

Indian-headquartered generic and OTC pharmaceutical company with global presence including US, Europe, and emerging markets. Overlaps with Marksans in respiratory/cough-and-cold OTC, soft-gel capabilities, and US ANDA portfolio.

TypeDirect peer
Description

Marksans was originally incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals before spinning off in 2003. Both are Indian-headquartered generic pharmaceutical companies with similar therapeutic-area focus and US/UK distribution presence, making Glenmark a direct legacy peer.

TypeBroad incumbent
Description

India-headquartered integrated pharmaceutical company with comparable US generics franchise, similar ANDA-driven business model, and global manufacturing footprint. Larger scale and broader specialty/biologics pipeline than Marksans.

TypeDirect peer
Description

Large Indian generic pharmaceutical company with comparable manufacturing scale, US/EU regulatory approvals, and finished dosage form focus. Both target similar US generic opportunities and operate multi-site manufacturing across India with global distribution networks.

TypeDirect peer
Description

Indian mid-cap generic pharmaceutical company with US and emerging-markets presence, comparable finished dosage form focus, and similar revenue scale. Marksans recently acquired three Teva entities (Ireland, Canada, Nova Australia), making Torrent a relevant market overlap peer.

TypeDirect peer
Description

Indian-headquartered pharmaceutical company with similar generic dosage-form portfolio, US ANDA pipeline, and global distribution. Operates in many of the same therapeutic categories as Marksans, including cardiovascular, CNS, and anti-diabetic segments.

TypeDirect peer
Description

Indian-headquartered generic pharmaceutical company with comparable manufacturing footprint in India, US, and other regulated markets, and similar finished dosage form (tablets, capsules, liquids, ointments) focus at a similar revenue scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marksans Pharma

Generic Pharmaceuticalsmarksanspharma.com

Marksans Pharma is an Indian publicly listed generic pharmaceutical manufacturer producing tablets, capsules, oral liquids, and ointments across four facilities in India, the US, and UK, distributing 300+ products through wholly-owned subsidiaries to retail chains, wholesalers, and hospitals in 50+ countries with 95% of revenue from regulated markets.

What Marksans Pharma does

Marksans Pharma Limited is a publicly listed Indian pharmaceutical company (NSE: MARKSANS, BSE: 524404) that develops, manufactures, and markets finished dosage generic pharmaceutical formulations for global regulated markets. Founded in 2001 as a wholly-owned subsidiary of Glenmark Pharmaceuticals and spun off as an independent entity in 2003, the company operates four manufacturing facilities — two in Goa, India (Verna and North Goa), one in Farmingdale, USA (Time-Cap Labs), and one in Southport, UK — producing tablets, hard and soft gelatin capsules, oral liquids, and ointments. Combined annual capacity is 8 billion units, on track to double to 16 billion units following the Tevapharm India acquisition. The portfolio comprises 300+ products and 1,500+ SKUs across OTC consumer self-care (pain, cough/cold, allergy, digestive, vitamins, skin) and prescription therapeutic segments (cardiovascular, CNS, oncology, anti-diabetics, antibiotics), backed by 50+ FDA-approved products, 350+ filed dossiers, and 300+ ANDA/MA approvals.

The company runs a vertically integrated, B2B contract-manufacturing and distribution model. Revenue is generated through negotiated supply agreements with major retail chains, pharmacy wholesalers, and hospital systems in the US, UK, Europe, Australia, Canada, MENA, and emerging markets — 95% of revenue comes from regulated jurisdictions. Distribution is executed through wholly-owned subsidiaries: Time-Cap Labs (US), Bell's Healthcare and Relonchem (UK), Nova Pharmaceuticals (Australasia), Access Healthcare (MENA), and QliniQ B.V. (Netherlands, acquired June 2026). R&D is conducted across four centers with 50+ scientists accredited by US-FDA, UK MHRA, and Australian TGA. With FY26 consolidated revenue of approximately ₹29,509 million (~$355M USD) and net profit of ₹4,200.64 million, the company is positioned as a mid-tier Indian generic exporter with an accelerating M&A-led geographic expansion strategy across the US, EU, Canada, and Australasia.

Marksans Pharma firmographics

Firmographics
Name
Marksans Pharma
Legal name
Marksans Pharma Limited
Website
https://marksanspharma.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Marksans Pharma is an Indian publicly listed generic pharmaceutical manufacturer producing tablets, capsules, oral liquids, and ointments across four facilities in India, the US, and UK, distributing 300+ products through wholly-owned subsidiaries to retail chains, wholesalers, and hospitals in 50+ countries with 95% of revenue from regulated markets.
Ownership category
akta.pro rank

Marksans Pharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical formulations
  • OTC medications
  • Prescription drugs
  • CRAMS services

Where Marksans Pharma is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices5 records

Markets served

Marksans Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Pharmaceutical Formulations: Research, manufacturing, and marketing of finished dosage pharmaceutical formulations. Revenue generated from sale of generic drugs across OTC and prescription categories. The company operates in regulated markets (US, Europe, Australia) contributing 95% of revenue.
  2. OTC Products: Over-the-counter consumer self-care products including pain management, cough and cold, digestive health, vitamins, supplements, and anti-allergic medications. Sold through retail chains and pharmacies.
  3. Prescription (Rx) Drugs: Prescription medications for cardiovascular diseases, central nervous system disorders, diabetes, oncology, and antibiotics. Distributed through wholesalers, retailers, and hospitals.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B pharmaceutical sales model

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Marksans Pharma product offering

Product offering

Core offering

Marksans Pharma is a publicly listed Indian pharmaceutical company that researches, manufactures, and markets finished dosage generic pharmaceutical formulations, including tablets, capsules, oral liquids, and ointments, across OTC and prescription segments. The company operates four manufacturing facilities in India, the UK, and the USA, producing over 300 products and 1,500+ SKUs distributed to retailers, wholesalers, and pharmacy chains in regulated markets globally.

Product overview

Marksans Pharma operates a diversified pharmaceutical formulation business with four manufacturing facilities located in India (Verna Goa and North Goa), United States (Farmingdale), and United Kingdom (Southport). The company offers a comprehensive portfolio of 300+ products and 1500+ SKUs across two main categories: OTC Consumer Self-Care Products (Pain Management, Cough & Cold, Allergy, Digestive Health, Vitamins/Minerals/Supplements, Skin Care) and Prescription Rx Therapeutic Segments (Cardiovascular, CNS, Oncology, Anti-Diabetics, Anti-Biotics). The portfolio is supported by subsidiary brands including Bells Healthcare (UK), Nova Pharmaceuticals (Australia), Relonchem (UK), Time-Cap Labs (USA), Access Healthcare (UAE/MENA), and QliniQ BV (Netherlands). Manufacturing capabilities include tablets, hard/soft gelatin capsules, oral liquids, and ointments with accreditations from US FDA, UK MHRA, Australian TGA, EU Health Authority, Health Canada, and Japanese Health Authority.

Differentiator

Problem solved

Functional benefit

Brands

  • Bells Healthcare: Over-the-counter and prescription pharmaceuticals brand specializing in own-label products including analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care
  • Nova
  • Relonchem
  • Time-Cap Labs
  • QliniQ

Products and services

  • OTC Consumer Self-Care Products Over-the-counter consumer healthcare products including pain management (arthritis), upper respiratory (cough & cold, allergy), digestive health, vitamins/minerals/supplements, and skin care products distributed through retail and pharmacy chains.
  • Prescription (Rx) Therapeutic Segments Prescription pharmaceutical products covering cardiovascular system, central nervous system, oncology, anti-diabetics, and anti-biotics therapeutic segments, distributed to wholesalers, retailers, and hospitals.
  • Bells Healthcare (Bell, Sons & Co. Druggists) Ltd UK-based manufacturer of over-the-counter and prescription pharmaceuticals with over 100 MHRA-registered licenses, specializing in own-label products across analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care. Largest manufacturer of private-label and branded cough liquids in the UK.
  • Nova Pharmaceuticals Australasia Australian pharmaceutical company engaged in R&D and marketing of generic OTC products with focus on analgesics, antihistamines, anti-fungal, anti-allergy, dermatology, essential oils, and gastrointestinal segments. All products comply with TGA Australia regulations.
  • Relonchem Limited UK-based company engaged in licensing, marketing, and distribution of prescription generic pharmaceutical products to wholesalers, retailers, and hospitals. Portfolio includes own-label products in anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, allergy relief, anti-viral, and pain relief categories.
  • Time-Cap Labs Inc. US-based manufacturer of solid-dose generic pharmaceutical products operating in OTC and prescription pharmaceutical markets. Products include Gastrointestinal, Laxatives, Pain Management, Analgesics, Cold and Cough, and Anti-Allergy categories sold through major pharmacy chains, distributors, and wholesalers.
  • Access Healthcare for Medical Products L.L.C. Dubai-based pharmaceutical marketing and promotion company providing strategic partners with opportunities to grow business in the MENA region, with in-depth knowledge of local pharmaceutical market and business culture.
  • QliniQ BV Netherlands-based company representing world leading manufacturers of medical devices and medicines. Operates niche products across women's health, dermatology, respiratory care, and specialty segments, manufactured within EU with Netherlands, Germany, and Spain as main manufacturing countries.

Quantifiable outcome

  • FY26 net profit grew 9.8% to ₹4,200.64 million
  • +3 more outcomes

Companies that use Marksans Pharma

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Marksans Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Marksans Pharma partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Marksans Pharma competitors and assessment

Company assessment

Direct peers

  • Lupin Limited: Indian-headquartered generic pharmaceutical manufacturer with a comparable global footprint across the US, Europe, and emerging markets, similar dosage-form portfolio (oral solids, injectables, complex generics), and similar revenue scale. Both compete head-to-head in US generic ANDAs and UK/EU markets.
  • Alkem Laboratories: Indian pharmaceutical company with comparable India-manufacturing-plus-US-distribution model, similar therapeutic-area breadth across OTC and prescription generics, and overlapping US ANDA filings. Comparable revenue scale and growth profile.
  • Cipla Limited: Indian-headquartered generic and OTC pharmaceutical company with global presence including US, Europe, and emerging markets. Overlaps with Marksans in respiratory/cough-and-cold OTC, soft-gel capabilities, and US ANDA portfolio.
  • Glenmark Pharmaceuticals: Marksans was originally incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals before spinning off in 2003. Both are Indian-headquartered generic pharmaceutical companies with similar therapeutic-area focus and US/UK distribution presence, making Glenmark a direct legacy peer.
  • Aurobindo Pharma: Large Indian generic pharmaceutical company with comparable manufacturing scale, US/EU regulatory approvals, and finished dosage form focus. Both target similar US generic opportunities and operate multi-site manufacturing across India with global distribution networks.
  • Torrent Pharmaceuticals: Indian mid-cap generic pharmaceutical company with US and emerging-markets presence, comparable finished dosage form focus, and similar revenue scale. Marksans recently acquired three Teva entities (Ireland, Canada, Nova Australia), making Torrent a relevant market overlap peer.
  • Zydus Lifesciences (Cadila Healthcare): Indian-headquartered pharmaceutical company with similar generic dosage-form portfolio, US ANDA pipeline, and global distribution. Operates in many of the same therapeutic categories as Marksans, including cardiovascular, CNS, and anti-diabetic segments.
  • Strides Pharma Science: Indian-headquartered generic pharmaceutical company with comparable manufacturing footprint in India, US, and other regulated markets, and similar finished dosage form (tablets, capsules, liquids, ointments) focus at a similar revenue scale.

Broad incumbents

  • Sun Pharmaceutical Industries: India's largest pharmaceutical company and the dominant Indian generic player globally. Operates across the same dosage forms and therapeutic areas as Marksans but at substantially greater scale, with broader specialty and branded-generic exposure.
  • Dr. Reddy's Laboratories: India-headquartered integrated pharmaceutical company with comparable US generics franchise, similar ANDA-driven business model, and global manufacturing footprint. Larger scale and broader specialty/biologics pipeline than Marksans.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Marksans Pharma social profiles

Digital presence

Marksans Pharma compliance and trust

Trust signal

Compliance5 records

Marksans Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marksans Pharma leadership team

Management profile

Number of profiles

Profiles13 records

Marksans Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Marksans Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marksans Pharma M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marksans Pharma

What does Marksans Pharma do?

Marksans Pharma is a publicly listed Indian pharmaceutical company that researches, manufactures, and markets finished dosage generic pharmaceutical formulations, including tablets, capsules, oral liquids, and ointments, across OTC and prescription segments. The company operates four manufacturing facilities in India, the UK, and the USA, producing over 300 products and 1,500+ SKUs distributed to retailers, wholesalers, and pharmacy chains in regulated markets globally.

Is Marksans Pharma a public or private company?

Marksans Pharma is a public company. It is classified as public and is currently operating.

When was Marksans Pharma founded?

Marksans Pharma was founded in 1992. It employs 1,001 to 5,000 people.

Where is Marksans Pharma based?

Marksans Pharma is headquartered in Mumbai, India, in the Asia region.

How does Marksans Pharma make money?

Three revenue lines are on record. Generic Pharmaceutical Formulations are the primary driver. The others are OTC Products and prescription (Rx) Drugs.

Who are Marksans Pharma's main competitors?

Direct peers on record are Lupin Limited, Alkem Laboratories, Cipla Limited, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals, Zydus Lifesciences (Cadila Healthcare) and Strides Pharma Science. Broad incumbents are Sun Pharmaceutical Industries and Dr. Reddy's Laboratories.

Does Marksans Pharma have an API?

No public API is recorded for Marksans Pharma.

What industry is Marksans Pharma in?

Marksans Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business News TodayTrade Spotlight: How should you trade Phoenix Mills, Paytm, Radico Khaitan, JK Tyre, Marksans Pharma, and others on November 13?- Moneycontrol.comMoneycontrol's Moneycontrol.com published technical trading ideas for Phoenix Mills, Paytm, Radico Khaitan, JK Tyre, Marksans Pharma, and others on November 13. The ideas include buy strategies with specific targets and stop-losses, such as Phoenix Mills targeting Rs 2,550 and Paytm targeting Rs 2,130.Simply Wall StMarksans Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarksans Pharma's quarterly results showed revenue of ₹9.4b, beating expectations, but statutory EPS of ₹3.11 missed forecasts by 11%. Analysts now forecast 2027 revenue of ₹35.7b and EPS of ₹12.55, with a consensus price target of ₹324 unchanged.Business News TodayBuy Marksans Pharma; target of Rs 385 Choice Institutional Equities- Moneycontrol.comChoice Institutional Equities maintains a BUY rating on Marksans Pharma, targeting INR 385. The company is expected to reach INR 40 billion revenue by FY28E, with EBITDA margin of 21.5–23%. Revenue, EBITDA, and PAT are forecast to grow at CAGRs of 17.5%, 22.3%, and 24.5% over FY26–29E.TradingViewBuy Marksans Pharma; target of Rs 385 Choice Institutional EquitiesChoice Institutional Equities maintains a positive view on Marksans Pharma, forecasting revenue growth of 17.5% CAGR over FY26–29E. The company targets INR 40 billion revenue by FY28E, with a target price of INR 385 and a 'BUY' rating.ScanXMarksans Pharma approves ₹0.90 dividend, reappoints directors at AGMMarksans Pharma's 34th annual general meeting on August 27, 2026 approved a final dividend of ₹0.90 per share, adopted FY26 audited financials and reappointed directors. Promoters voted 100%, institutions 80.76%, with 3,543,780 votes against Dr. Sunny Sharma's reappointment.Business TodayMarksans Pharma, Biocon सहित इन फार्मा स्टॉक पर एक्सपर्ट वैशाली पारेख की नजर- आपके पोर्टफोलियो में कौन-कौन है?In a Business Today show, analyst Vaishali Parekh advised caution on Biocon, saying its momentum fades whenever the stock is discussed, but she sees a breakout potential near 425-430 rupees toward 480. She favored Sun Pharma, holding with a stop-loss, and noted gains in Glenmark and Laurus Labs. She also cited Marksans Pharma and Morepen Labs as breakout-ready.AInvestMarksans Pharma Pays a Dividend, But at 0.27% It's Not an Income PlayMarksans Pharma declared a ₹0.90 per share dividend with a 0.27% yield while reporting strong financial performance, including FY26 revenue of ₹29,509 crore and Q1 FY27 EBITDA growth of 113%. The company is prioritizing reinvestment into global expansion and manufacturing capacity over higher immediate payouts, targeting $400 million in US revenue within five years. Consequently, the stock is positioned as a growth investment trading at a high multiple rather than an income asset.Simply Wall StMarksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend SoonMarksans Pharma Limited is scheduled to trade ex-dividend on August 20th, with a dividend payment of ₹0.90 per share set for September 26th. The company maintains a sustainable dividend supported by a low payout ratio of 9.8% and consistent earnings growth of 14% annually over the past five years.Simply Wall StMarksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearMarksans Pharma Limited reported first-quarter statutory profits of ₹3.47 per share, exceeding analyst estimates and triggering a 22% surge in its share price. Following these results, three analysts upgraded their revenue and earnings forecasts for 2027, raising the consensus price target by 22% to ₹324 per share.YahooMarksans Pharma Ltd (BOM:524404) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit ...Marksans Pharma reported record financial results for Q1 2027, with revenue rising 35.6% to INR 841 crores and profit after tax surging 173.9% to INR 159.4 crores. The company achieved a cash balance exceeding INR 1,000 crores and improved its working capital cycle to 132 days, while management reaffirmed a target of INR 4,000 crore revenue within two years.